Targets › TNFRSF10B
1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2026.
Receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. (UniProt, O14763)
Open in Phaseline: the race on TNFRSF10B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Inhibrx Biosciences | INBRX-109 Tetravalent DR5 agonist antibody | TNFRSF10B | Phase 2 | Conventional Chondrosarcoma; Ewing Sarcoma | Dec 2026 |
Conventional Chondrosarcoma (1) Ewing Sarcoma (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.